



# Iowa Department of Human Services

Terry E. Branstad  
Governor

Kim Reynolds  
Lt. Governor

Charles M. Palmer  
Director

## Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting

October 1, 2014

**Location: Learning Resource Center  
Fairmeadows Room  
3550 Mills Civic Parkway  
West Des Moines, Iowa**

**Time: 9:30 a.m. – 1:30 p.m.**

### Final Agenda

1. Welcome & Introductions
  - a) Commission Members and Staff
  - b) Approval of the Minutes
2. Commission Business
  - a) DHS Recommendation Letter – August 2014
  - b) P&T Recommendation Letter – August 2014
3. IME Updates
4. Prevalence Report Summary
5. Case Studies
6. Public Comment (See Conflict of Interest Disclosure Form)
7. ProDUR Edit
  - a) Antipsychotics - Age Edit and Duplicate Therapy Edit - Update
8. Focus Studies/Provider Education Initiatives
  - a) Valproate Use for Migraine in Females – Follow Up
  - b) Ketoconazole Utilization – Follow Up
  - c) Overutilization of Opioids – Follow Up
  - d) Opioid Utilization Potential Drug Seeking Behavior – Follow Up
  - e) Valproate Use in Women of Childbearing Age without Seizure or Bipolar Diagnosis – Follow Up
  - f) Valproate Use in Women of Childbearing Age with Seizure or Bipolar Diagnosis – Follow Up
  - g) Long Term Use of Short-Acting Opioids – Updated

- h) Duplicate Antipsychotics – Updated
  - i) Duplicate Benzodiazepines – Initial Review
  - j) Niacin Utilization – Initial Review
9. Public Comment (See Conflict of Interest Disclosure Form)
10. Prior Authorization
- a) Annual Review of Prior Authorization Criteria
  - b) Vorapaxar (Zontivity™) – Initial Review
  - c) Ceritinib (Zykadia™) – Initial Review
  - d) Chronic Pain Syndromes – Second Review
  - e) Oral Immunotherapy – Second Review
  - f) Methotrexate Injection – Second Review
  - g) Tasimelteon (Helitox™) – Second Review
  - h) Apremilast (Otezla®) – Second Review
  - i) Palivizumab (Synagis®) – Second Review
11. Miscellaneous
- a) DUR Digest Vol. 27, No. 1 – Second Review
  - b) MedWatch
  - c) Off-label Pharmaceutical Marketing - <http://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Downloads/off-label-marketing-factsheet.pdf>
12. Executive Closed Session
- a) Approval of Minutes
  - b) Member Profiles
13. Adjournment

Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted twice during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

**[www.iadur.org](http://www.iadur.org)**

For more information contact the DUR Project Coordinator, Pamela Smith, R.Ph., at [info@iadur.org](mailto:info@iadur.org) or (515) 974-3131

**\*\*\*Next Meeting December 3, 2014\*\*\*  
at the West Des Moines Learning Resource Center  
3550 Mills Civic Parkway, West Des Moines**